Your browser doesn't support javascript.
Clinical efficacy analysis of mesenchymal stem cell therapy in patients with COVID-19: A systematic review.
Cao, Jun-Xia; You, Jia; Wu, Li-Hua; Luo, Kai; Wang, Zheng-Xu.
  • Cao JX; Biotherapy Center, The Seventh Medical Center of People's Liberation Army General Hospital, Beijing 100700, China.
  • You J; Biotherapy Center, The Seventh Medical Center of People's Liberation Army General Hospital, Beijing 100700, China.
  • Wu LH; Biotherapy Center, The Seventh Medical Center of People's Liberation Army General Hospital, Beijing 100700, China.
  • Luo K; Biotherapy Center, The Seventh Medical Center of People's Liberation Army General Hospital, Beijing 100700, China.
  • Wang ZX; Biotherapy Center, The Seventh Medical Center of People's Liberation Army General Hospital, Beijing 100700, China. zhxuwang@qq.com.
World J Clin Cases ; 10(27): 9714-9726, 2022 Sep 26.
Article in English | MEDLINE | ID: covidwho-2164268
ABSTRACT

BACKGROUND:

Currently, ongoing trials of mesenchymal stem cells (MSC) therapies for coronavirus disease 2019 (COVID-19) have been reported.

AIM:

In this study, we investigated whether MSCs have therapeutic efficacy in novel COVID-19 patients.

METHODS:

Search terms included stem cell, MSC, umbilical cord blood, novel coronavirus, severe acute respiratory syndrome coronavirus-2 and COVID-19, applied to PubMed, the Cochrane Controlled Trials Register, EMBASE and Web of Science.

RESULTS:

A total of 13 eligible clinical trials met our inclusion criteria with a total of 548 patients. The analysis showed no significant decrease in C-reactive protein (CRP) levels after stem cell therapy (P = 0.11). A reduction of D-dimer levels was also not observed in patients after stem cell administration (P = 0.82). Furthermore, interleukin 6 (IL-6) demonstrated no decrease after stem cell therapy (P = 0.45). Finally, we investigated the overall survival (OS) rate after stem cell therapy in COVID-19 patients. There was a significant improvement in OS after stem cell therapy; the OS of enrolled patients who received stem cell therapy was 90.3%, whereas that of the control group was 79.8% (P = 0.02).

CONCLUSION:

Overall, our analysis suggests that while MSC therapy for COVID-19 patients does not significantly decrease inflammatory markers such as CRP, D-dimer and IL-6, OS is improved.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study / Reviews / Systematic review/Meta Analysis Language: English Journal: World J Clin Cases Year: 2022 Document Type: Article Affiliation country: Wjcc.v10.i27.9714

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study / Reviews / Systematic review/Meta Analysis Language: English Journal: World J Clin Cases Year: 2022 Document Type: Article Affiliation country: Wjcc.v10.i27.9714